Last reviewed · How we verify

Recombinant Human Interferon α-2b Spray

Children's Hospital of Fudan University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Recombinant Human Interferon α-2b Spray is a Small molecule drug developed by Children's Hospital of Fudan University. It is currently FDA-approved.

Recombinant Human Interferon α-2b Spray is a protein-based drug that acts as an agonist to the Interferon alpha/beta receptor. It has been studied in clinical trials for conditions including Novel Coronavirus Pneumonia, 2019-nCoV, and Herpangina.

At a glance

Generic nameRecombinant Human Interferon α-2b Spray
SponsorChildren's Hospital of Fudan University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Recombinant Human Interferon α-2b Spray

What is Recombinant Human Interferon α-2b Spray?

Recombinant Human Interferon α-2b Spray is a Small molecule drug developed by Children's Hospital of Fudan University.

Who makes Recombinant Human Interferon α-2b Spray?

Recombinant Human Interferon α-2b Spray is developed and marketed by Children's Hospital of Fudan University (see full Children's Hospital of Fudan University pipeline at /company/children-s-hospital-of-fudan-university).

What development phase is Recombinant Human Interferon α-2b Spray in?

Recombinant Human Interferon α-2b Spray is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing